We were delighted to talk with Dr Rolof Gijtenbeek (Medical Center Leeuwarden, Leeuwarden, The Netherlands) around his abstract on ‘Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study.‘, (Presentation ID 4324) which was presented at ERS International Congress 2021, 5-8 September 2021.
Questions
- EGFR tyrosine kinase inhibitors such as erlotinib are indicated in the treatment of EGFR mutated non-small cell lung cancer (NSCLC) – what are the current challenges with treatment? (0:12)
- What evidence already existed on the effect of combining EGFR tyrosine kinase inhibitors and chemotherapy in NSCLC? (1:15)
- Please can you outline the key methodology used in the NVALT 17 study? (2:30)
- How did patients respond in terms of efficacy and safety in the NVALT 17 study? (3:45)
- What are the implications of this study for patients with NSCLC and future research? (4:20)
Disclosures: Rolof Gijtenbeek has nothing to disclose in relation to this video. Presentation slides shared with permission from the author.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ERS 2021 (Virtual).
